

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1001
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733

RECEIVED OCT 29 2004 File Information Unit	In re Application of <u>Hitzman</u>
	Application Number: <u>06/811088</u>
	Filed <u>3/16/01</u>
	Page No. <u>#13</u>

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file records of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. 2003/0125540, page, _____ line _____
United States Patent Number _____, column _____, line, _____ or
WIPO Pub. No. _____, page _____, line _____

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows. For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(b), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

[Signature]

Signature

Rick Toman

Typed or printed name

Registration Number, if applicable

703-418-2848

Telephone Number

10/29/04
Date

FOR PTO USE ONLY

RECEIVED
Approved by: <u>[Signature]</u>
OCT 29 2004
Unit: <u>File Information Unit</u>

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit to the public which is in the public interest and to the U.S. Patent and Trademark Office. This collection is estimated to take 12 minutes to complete, including reviewing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the burden of this collection of information, including suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1430, Alexandria, VA 22303-1430. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.

If you need assistance in completing the form call 1-800-595-9122



US 20030125540A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2003/0125540 A1**
Holtzman et al. (43) **Pub. Date: Jul. 3, 2003**(54) **NOVEL GENES ENCODING PROTEINS
HAVING PROGNOSTIC, DIAGNOSTIC,
PREVENTIVE, THERAPEUTIC AND OTHER
USES**(52) **U.S. Cl. 536/23.5; 530/350; 530/388.23;
435/69.5; 435/320.1; 435/325;
435/6; 435/7.2**(75) **Inventors: Douglas A. Holtzman, Jamaica Plain,
MA (US); David P. Gearing, Victoria
(AU); Yang Pan, Bellevue, WA (US)**(57) **ABSTRACT****Correspondence Address:
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139 (US)**(73) **Assignee: Millennium Pharmaceuticals, Inc.**(21) **Appl. No.: 10/314,410**(22) **Filed: Dec. 6, 2002****Related U.S. Application Data**(60) **Continuation of application No. 09/811,088, filed on
Mar. 16, 2001, now abandoned, which is a continu-
ation-in-part of application No. 09/712,726, filed on
Nov. 14, 2000, now abandoned, and which is a
continuation-in-part of application No. 09/757,421,
filed on Jan. 10, 2001, now abandoned, and which is
a continuation-in-part of application No. 08/843,651,
filed on Apr. 16, 1997, now abandoned, and which is
a continuation-in-part of application No. 09/354,809,
filed on Jul. 16, 1999, now abandoned, which is a
division of application No. 08/938,365, filed on Sep.
26, 1997, now Pat. No. 5,989,909.****Publication Classification**(51) **Int. Cl.⁷ C12Q 1/68; G01N 33/53;
G01N 33/567; C07H 21/04;
C07K 14/52**

The invention relates to the discovery and characterization of several genes and the polypeptides they encode: thymotaxin (Tango-45), Tango-63d, Tango-63e, Tango-67, and huchordin (Tango-66). Thymotaxin is a new member of the C—C family of chemokines. Tango-63d and Tango-63e are two novel polypeptides within the tumor necrosis factor (TNF) receptor superfamily. Tango-67 is related to a number of growth factors, particularly members of the connective tissue growth factor family. Huchordin is related to chordin, a known protein that is involved in the induction of twinned axes, can completely rescue axial development in ventralized embryos, is a potent dorsalizing factor, and plays a crucial role in regulating cell-cell interactions in the organizing centers of head, trunk, and tail development. The invention encompasses nucleic acid molecules encoding nucleic acids and polypeptides of the invention, or mutant forms thereof that encode dysfunctional receptor polypeptides, vectors containing these nucleic acid molecules, cells harboring recombinant DNA molecules encoding nucleic acids or polypeptides of the invention, or mutant forms thereof, host fusion proteins that include functional or dysfunctional polypeptides of the invention, transgenic animals that express nucleic acids or polypeptides of the invention, screening methods and therapeutic methods employing the nucleic acid molecules and polypeptides described above, substantially purified nucleic acids and polypeptides of the invention, and therapeutic compositions containing these nucleic acid molecules and polypeptides.